Tissue Distribution
"Tissue Distribution" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Accumulation of a drug or chemical substance in various organs (including those not relevant to its pharmacologic or therapeutic action). This distribution depends on the blood flow or perfusion rate of the organ, the ability of the drug to penetrate organ membranes, tissue specificity, protein binding. The distribution is usually expressed as tissue to plasma ratios.
Descriptor ID |
D014018
|
MeSH Number(s) |
G03.787.917 G07.690.725.949
|
Concept/Terms |
Tissue Distribution- Tissue Distribution
- Distribution, Tissue
- Distributions, Tissue
- Tissue Distributions
|
Below are MeSH descriptors whose meaning is more general than "Tissue Distribution".
Below are MeSH descriptors whose meaning is more specific than "Tissue Distribution".
This graph shows the total number of publications written about "Tissue Distribution" by people in this website by year, and whether "Tissue Distribution" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1980 | 0 | 2 | 2 | 1981 | 0 | 2 | 2 | 1982 | 0 | 3 | 3 | 1983 | 0 | 2 | 2 | 1984 | 0 | 3 | 3 | 1985 | 0 | 4 | 4 | 1986 | 0 | 2 | 2 | 1988 | 0 | 3 | 3 | 1989 | 0 | 5 | 5 | 1990 | 0 | 7 | 7 | 1991 | 0 | 5 | 5 | 1992 | 0 | 4 | 4 | 1993 | 0 | 11 | 11 | 1994 | 0 | 12 | 12 | 1995 | 0 | 11 | 11 | 1996 | 0 | 6 | 6 | 1997 | 0 | 5 | 5 | 1998 | 0 | 4 | 4 | 1999 | 0 | 11 | 11 | 2000 | 0 | 11 | 11 | 2001 | 0 | 7 | 7 | 2002 | 0 | 10 | 10 | 2003 | 0 | 10 | 10 | 2004 | 0 | 11 | 11 | 2005 | 0 | 12 | 12 | 2006 | 0 | 9 | 9 | 2007 | 0 | 9 | 9 | 2008 | 0 | 7 | 7 | 2009 | 0 | 4 | 4 | 2010 | 0 | 7 | 7 | 2011 | 0 | 4 | 4 | 2012 | 0 | 6 | 6 | 2013 | 0 | 7 | 7 | 2014 | 0 | 11 | 11 | 2015 | 0 | 7 | 7 | 2016 | 0 | 4 | 4 | 2017 | 0 | 5 | 5 | 2018 | 0 | 2 | 2 | 2019 | 0 | 9 | 9 | 2020 | 0 | 5 | 5 | 2021 | 0 | 4 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Tissue Distribution" by people in Profiles.
-
Sudo H, Tsuji AB, Sugyo A, Harada Y, Nagayama S, Katagiri T, Nakamura Y, Higashi T. FZD10-targeted a-radioimmunotherapy with 225 Ac-labeled OTSA101 achieves complete remission in a synovial sarcoma model. Cancer Sci. 2022 Feb; 113(2):721-732.
-
Benzon HT, Maus TP, Kang HR, Provenzano DA, Bhatia A, Diehn F, Nelson A, McCormick ZL, Liu BP, de Andres Ares J, Anitescu M, Blackham K, Bhaskar A, Brill S, Collins J, Gulve A, Hurley RW, Jeon YH, Moon JY, Rauck RL, Rodes M, Lee RK, Shah V, Shanthanna H, van Zundert J, Huntoon M, Rathmell JP, Borges MS, Cohen SP, Greenberger PA. The Use of Contrast Agents in Interventional Pain Procedures: A Multispecialty and Multisociety Practice Advisory on Nephrogenic Systemic Fibrosis, Gadolinium Deposition in the Brain, Encephalopathy After Unintentional Intrathecal Gadolinium Injection, and Hypersensitivity Reactions. Anesth Analg. 2021 08 01; 133(2):535-552.
-
Tannock IF, Ratain MJ, Goldstein DA, Lichter AS, Rosner GL, Saltz LB. Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments. J Clin Oncol. 2021 03 20; 39(9):950-955.
-
Zhang HJ, Mitchell S, Fang YH, Tsai HM, Piao L, Ousta A, Leoni L, Chen CT, Sharp WW. Assessment of Brain Glucose Metabolism Following Cardiac Arrest by [18F]FDG Positron Emission Tomography. Neurocrit Care. 2021 02; 34(1):64-72.
-
Floege J, Funk F, Ketteler M, Rastogi A, Walpen S, Covic AC, Sprague SM. Iron kinetics following treatment with sucroferric oxyhydroxide or ferric citrate in healthy rats and models of anaemia, iron overload or inflammation. Nephrol Dial Transplant. 2020 06 01; 35(6):946-954.
-
Chiang AC, Sequist LVD, Gilbert J, Conkling P, Thompson D, Marcoux JP, Gettinger S, Kowanetz M, Molinero L, O'Hear C, Fassò M, Lam S, Gordon MS. Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer. Clin Lung Cancer. 2020 09; 21(5):455-463.e4.
-
Strickler JH, LoRusso P, Salgia R, Kang YK, Yen CJ, Lin CC, Ansell P, Motwani M, Wong S, Yue H, Wang L, Reilly E, Afar D, Naumovski L, Ramanathan RK. Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors. Mol Cancer Ther. 2020 05; 19(5):1210-1217.
-
Piperno-Neumann S, Larkin J, Carvajal RD, Luke JJ, Schwartz GK, Hodi FS, Sablin MP, Shoushtari AN, Szpakowski S, Chowdhury NR, Brannon AR, Ramkumar T, de Koning L, Derti A, Emery C, Yerramilli-Rao P, Kapiteijn E. Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071. Mol Cancer Ther. 2020 04; 19(4):1031-1039.
-
Vij R, Nath R, Afar DEH, Mateos MV, Berdeja JG, Raab MS, Guenther A, Martínez-López J, Jakubowiak AJ, Leleu X, Weisel K, Wong S, Gulbranson S, Sheridan JP, Reddy A, Paiva B, Singhal A, San-Miguel JF, Moreau P. First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma. Clin Cancer Res. 2020 05 15; 26(10):2308-2317.
-
Hargrave DR, Bouffet E, Tabori U, Broniscer A, Cohen KJ, Hansford JR, Geoerger B, Hingorani P, Dunkel IJ, Russo MW, Tseng L, Dasgupta K, Gasal E, Whitlock JA, Kieran MW. Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation-Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study. Clin Cancer Res. 2019 12 15; 25(24):7303-7311.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|